ICYMI, some of this week’s featured content includes a new podcast episode, video interviews about FDA delays and sunscreen recalls, articles on topline study results for alopecia areata and utilizing the psoriasis toolbox, plus more.
In this month’s “Meet the Aesthetic Expert” column, Will Kirby, DO, FAOCD, talks with Edrice Simmons, senior vice president for US brands for Allergan Aesthetics, an AbbVie company, about entering the aesthetics industry, innovation, and implementing approachable and representative marketing campaigns.
In this video interview, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).
Take a look behind the scenes at the Aesthetics Biomedical's "Perspectives: The Evolution of Aesthetics" symposium held July 24th in Orlando, Florida.
MediWound Ltd, announced the results for its CIDS trial studying NexoBrid as a treatment for children with severe thermal burns.
Immunotherapy agent nemvaleukin alfa was granted an FDA fast track designation for the treatment of patient’s mucosal melanoma for previously undergone treatment with an anti-PD-L1 therapy.
This week’s edition of The Mainstream Patient features stories about purchasing non-toxic sunscreen, biologics for psoriasis, biotin for hair growth, "bacne", plus more.
Joshua Zeichner, MD, associate professor of dermatology and director of cosmetic & clinical research in dermatology, Mount Sinai Hospital, New York, discusses the impact of the recent FDA approval of Twyneo (Sol-Gel) for the treatment of acne.
In this video interview, David Light, CEO of Valisure, shares his thoughts on the recent sunscreen recall from Johnson & Johnson due to benzene contamination and reveals how the FDA and sun protection companies can make sure this never happens again.
In this episode, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).
In this video interview, Jerry Bagel, MD, MS, discusses improvement in quality of life for pediatric psoriasis patients and current and emerging treatments.
Ritlecitinib, an investigational covalent kinase inhibitor, achieved its primary endpoint and demonstrated statistically significant efficacy compared to placebo in treating alopecia areata.
The results from the Heads Up study were published in JAMA Dermatology, which demonstrated upadacitinib was superior to dupilumab in treating atopic dermatitis.
The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.
Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.